Treatment related damage in the ANCA-associated vasculitides: An analysis of cohorts from the European Vasculitis Study Group (EUVAS) therapeutic trials

Treatment related damage in the ANCA-associated vasculitides: An analysis of cohorts from the European Vasculitis Study Group (EUVAS) therapeutic trials

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Robson, J, Doll, H, Flossmann, O, Ravi, S, Lorraine, H, Peter, H, David, J, Chetan, M, Kerstin, W, Raashid, L
التنسيق:	Journal article
منشور في:	2013

مواد مشابهة

Factors associated with long-term damage in the ANCA-associated vasculitides: An analysis of cohorts from the European vasculitis study group (EUVAS) therapeutic trials
حسب: Robson, J, وآخرون
منشور في: (2013)

Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials.
حسب: Robson, J, وآخرون
منشور في: (2015)

Damage in the ANCA-associated vasculitides: Long-term data from the European Vasculitis Study Group (EUVAS) therapeutic trials
حسب: Robson, J, وآخرون
منشور في: (2015)

TREATMENT-RELATED DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS
حسب: Robson, J, وآخرون
منشور في: (2013)

FACTORS ASSOCIATED WITH LONG-TERM DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF COHORTS FROM THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS
حسب: Robson, J, وآخرون
منشور في: (2013)

Ongoing european research initiatives in systemic vasculitides: The EUVAS program
حسب: Luqmani, R, وآخرون
منشور في: (2005)

Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.
حسب: Robson, J, وآخرون
منشور في: (2014)

Classification criteria for the anca-associated vasculitides
حسب: Robson, J, وآخرون
منشور في: (2019)

ANCA-associated vasculitides in childhood
حسب: Szabó András, وآخرون
منشور في: (2011-09-01)

Long-term follow up of EUVAS studies
حسب: Flossmann, O, وآخرون
منشور في: (2007)

Glucocorticoid Treatment and Damage In The Antineutrophil- Cytoplasm Antibody Associated Vasculitides
حسب: Robson, J, وآخرون
منشور في: (2013)

THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS
حسب: Suppiah, R, وآخرون
منشور في: (2011)

THE DISEASE CHARACTERISTICS OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
حسب: Yew, S, وآخرون
منشور في: (2012)

Atherosclerosis in ANCA-associated systemic vasculitides
حسب: E I Kuznetsova, وآخرون
منشور في: (2012-06-01)

Towards diagnostic criteria for the ANCA-associated vasculitides.
حسب: Luqmani, R
منشور في: (2007)

French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides)
حسب: Benjamin Terrier, وآخرون
منشور في: (2020-12-01)

Cardiovascular outcomes in ANCA associated vasculitis
حسب: Mukhtyar, C, وآخرون
منشور في: (2008)

Correction to: French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides)
حسب: Benjamin Terrier, وآخرون
منشور في: (2021-04-01)

The role of rituximab in the treatment of ANCA-associated vasculitides (AAV)
حسب: Thomas Daikeler, وآخرون
منشور في: (2015-01-01)

Damage assessment in ANCA-associated vasculitis.
حسب: Bhamra, K, وآخرون
منشور في: (2012)

Outcome measures in ANCA-associated vasculitis.
حسب: Suppiah, R, وآخرون
منشور في: (2010)

International guidelines for the management ofANCA-associated systemic vasculitides
حسب: T. V. Beketova
منشور في: (2019-03-01)

Upper respiratory tract manifestations in patients with ANCA-associated vasculitides and their association with the presence and type of ANCA
حسب: I. G. Smirnova, وآخرون
منشور في: (2021-10-01)

THE DEMOGRAPHY OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
حسب: Yew, S, وآخرون
منشور في: (2012)

Explaining fatigue in ANCA-associated vasculitis.
حسب: Basu, N, وآخرون
منشور في: (2013)

Explaining fatigue in ANCA-associated vasculitis
حسب: Basu, N, وآخرون
منشور في: (2013)

Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides.
حسب: Exley, A, وآخرون
منشور في: (1997)

Relationship between serologic profile (ANCA type) and clinical features of renal involvement in ANCA-associated vasculitides
حسب: N M Bulanov, وآخرون
منشور في: (2018-06-01)

Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?
حسب: Zachary S. Wallace, وآخرون
منشور في: (2019-12-01)

Markers for work disability in ANCA-associated vasculitis
حسب: Basu, N, وآخرون
منشور في: (2013)

Long-term survival of ANCA-associated vasculitis
حسب: Flossmann, O, وآخرون
منشور في: (2009)

ANCA Associated Vasculitis Subtypes: Response [Response to Letter]
حسب: Austin K, وآخرون
منشور في: (2022-10-01)

Vasculites associadas ao anticorpo anticitoplasma de neutrófilo (Anca) Vasculitides associated to antineutrophil cytoplasmic antibodies (Anca)
حسب: Boris A. Cruz
منشور في: (2007-04-01)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.
حسب: Suppiah, R, وآخرون
منشور في: (2011)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials
حسب: Suppiah, R, وآخرون
منشور في: (2011)

ANCA-Associated Vasculitides and Hematologic Malignancies: Lessons from the Past and Future Perspectives
حسب: Marco Folci, وآخرون
منشور في: (2019-01-01)

A rare case of spontaneous renal rupture caused by ANCA - associated vasculitides
حسب: Yongquan Yu, وآخرون

EULAR recommendations for conducting clinical studies and/or clinical trials in ANCA-associated vasculitis
حسب: Luqmani, R, وآخرون
منشور في: (2007)

CONTEXTUALISING QUALITY OF LIFE IN ANCA ASSOCIATED VASCULITIS (AAV)
حسب: Basu, N, وآخرون
منشور في: (2012)

The characterisation and determinants of quality of life in ANCA associated vasculitis.
حسب: Basu, N, وآخرون
منشور في: (2014)